Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

  • days left to enroll
  • participants needed
  • sponsor
    Benaroya Research Institute
Updated on 15 February 2022
platelet count
measurable disease
biliary stents
ductal adenocarcinoma
pancreatic ductal adenocarcinoma


Using gemcitabine and nab-paclitaxel, the investigators hope to establish the differential ability of local and cytologically positive disease to respond to this regimen, and in particular, the frequency of cytologic conversion from positive to negative in such patients. The investigators also can begin to assess the value of maximum local therapy, including surgery, in patients who cytologically convert from positive to negative.


This research study is a Phase Ib clinical trial. It will assess the frequency of cytological conversion in patients with pancreatic adenocarcinoma and positive peritoneal cytology as a sole metastatic site following gemcitabine nab-paclitaxel.

Subjects must have a newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer with positive peritoneal cytology as a sole metastatic site and meet all inclusion/exclusion criteria.

Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be administered on days 1,8, and 15.

Condition Pancreatic Adenocarcinoma
Treatment Gemcitabine, Nab-paclitaxel
Clinical Study IdentifierNCT03703089
SponsorBenaroya Research Institute
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

Male, or a non-pregnant and non-lactating female
Age 18 years
Histologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)
Radiographic and pathologic staging (including staging laparoscopy with peritoneal wash) consistent with pancreatic cancer, resectable, borderline resectable, or locally advanced or unresectable as defined by NCCN guidelines (<>)
Laparoscopic confirmation that the PDAC is localized except for positive peritoneal cytology. Biliary stents are permitted
Elevated CA19-9
Measurable disease as defined by RECIST 1.1
ECOG performance status of 1 (see Appendix A)
Adequate bone marrow reserves as evidenced by
ANC 1,500 cells/l; and
Platelet count 100,000 cells/l; and
Hemoglobin 9 g/dL
Adequate hepatic function as evidenced by
Serum total bilirubin 1.5 ; and
AST and ALT 2.5 x ULN; and
Alkaline phosphatase 2.5 x ULN
Adequate renal function as evidenced by creatinine 1.5 x ULN
Women of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must
Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting gemcitabine/nab- paclitaxel (including dose interruptions) and for 3 months after last dose of gemcitabine/nab-paclitaxel and
Have a negative pregnancy test result at screening and agree to ongoing pregnancy testing at the Investigator's discretion during the course of the study. This applies even if the subject practices true abstinence from heterosexual contact
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with gemcitabine/nab-paclitaxel and for 3 months following the last dose of gemcitabine/nab- paclitaxel, even if he has undergone a successful vasectomy

Exclusion Criteria

Prior chemotherapy or radiation for pancreatic cancer
CA19-9 non-expressing
Previous (within the past 5 years) or concurrent, malignancy diagnosis, except non-melanoma skin cancer and in situ carcinomas
History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
Any medical or surgical condition that may place the subject at increased risk while on study
Any condition potentially decreasing compliance to study procedures
Participation in any other clinical protocol or investigational trials within 60 days prior to Day 1, Cycle 1
Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Current abuse of alcohol or illicit drugs
Any medical condition that, in the opinion of the Investigator, may pose a safety risk to the subject, may confound the assessment of safety and efficacy, or may interfere with study participation
Have Grade 2 pre-existing peripheral neuropathy (per CTCAE)
Inability or unwillingness to sign the informed consent form
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note